BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-30 22:05 |
Announcement of fully underwritten rights issue
|
English | 21.0 KB | ||
| 2025-06-30 22:00 |
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 19.5 KB | ||
| 2025-06-26 11:29 |
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerG…
|
Norwegian | 419.9 KB | ||
| 2025-06-26 11:29 |
BerGenBio ASA - Minutes from the annual general meeting 2025
|
English | 1.1 KB | ||
| 2025-06-03 19:22 |
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
|
English | 2.6 KB | ||
| 2025-06-03 15:55 |
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
|
Norwegian | 424.8 KB | ||
| 2025-06-03 15:55 |
BerGenBio ASA: Notice of Annual General Meeting
|
English | 2.6 KB | ||
| 2025-04-30 07:51 |
Financial calendar
|
English | 666 bytes | ||
| 2025-04-29 20:03 |
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
|
English | 3.9 MB | ||
| 2025-04-29 20:03 |
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
|
English | 2.8 MB | ||
| 2025-04-29 20:03 |
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
|
English | 2.6 KB | ||
| 2025-03-26 06:00 |
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in re…
|
English | 3.9 KB | ||
| 2025-03-17 06:00 |
BerGenBio announces advancement of its strategic review
|
English | 2.8 KB | ||
| 2025-02-26 06:00 |
BerGenBio Fourth Quarter Results 2024
|
English | 926.7 KB | ||
| 2025-02-26 06:00 |
BerGenBio Fourth Quarter Results 2024
|
English | 4.9 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
